Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Christine_Bunt
|
| gptkbp:developedBy |
therapies targeting macrophages
|
| gptkbp:focusesOn |
immuno-oncology
macrophage checkpoint modulation |
| gptkbp:foundedYear |
2017
|
| gptkbp:founder |
gptkb:Robert_Langer
gptkb:Christine_Bunt gptkb:Jerel_Davis |
| gptkbp:fundedBy |
gptkb:Alexandria_Venture_Investments
gptkb:InCube_Ventures gptkb:Leaps_by_Bayer gptkb:Northern_Biologics gptkb:Osage_University_Partners gptkb:Partners_Innovation_Fund gptkb:Qiming_Venture_Partners_USA gptkb:8VC gptkb:M_Ventures gptkb:Y_Combinator_Continuity |
| gptkbp:headquartersLocation |
gptkb:Bedford,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Verseau Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:therapeuticArea |
gptkb:cancer
immunotherapy |
| gptkbp:website |
https://www.verseautx.com/
|
| gptkbp:bfsParent |
gptkb:Stuart_Schreiber
|
| gptkbp:bfsLayer |
4
|